Pfizer Inc. Stock
€21.24
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -1.230% | 3.639% | -5.035% | -2.005% | 1.034% | -33.126% | -36.164% |
| BioMarin Pharmaceutical Inc. | -1.450% | -0.652% | 7.113% | 4.204% | 1.768% | -32.323% | -26.400% |
| Biogen Inc. | -9.720% | 0.779% | 6.295% | 59.965% | 22.603% | -25.800% | -38.524% |
| Zoetis Inc. A | -1.600% | 0.455% | -3.694% | -50.053% | -38.320% | -56.520% | -60.898% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
A high-yielding dividend may sound great for investors, but it can be a double-edged sword: when it's too high, investors start to worry about its safety. That's a big part of the reason why Pfizer
3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now
Many investors often associate high-yield dividend stocks with high risk. This concern makes sense, given how many high yielders end up turning into "yield traps," where a company cuts or suspends
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which